Avella Specialty Pharmacy

What Avella Specialty Pharmacy does

Avella Specialty Pharmacy is a Phoenix, Arizona-based specialty and compounding pharmacy founded in 1996, operating with 251-500 employees as a privately held for-profit company. The company provides personalized medications, specialized formulations, and clinical support services for patients requiring customized pharmaceutical solutions not available through standard commercial pharmacies, with a documented therapeutic focus on hepatitis and oncology. Its core offering addresses three primary problems: drug shortages, the absence of FDA-approved medications for specific patient needs, and the requirement for sterile medication preparation in complex therapy areas. Customers are segmented horizontally by use case rather than by industry, and the company is identified by Future Market Insights (September 2025) as one of three key industry players in the U.S. compounding pharmacy market alongside Fagron N.V. and Clinigen Group.

The company's operational foundation is its FDA-compliant sterile compounding facilities, which serve as the primary technical and regulatory differentiator. No proprietary technology platform, software products, AI systems, or digital infrastructure are documented in the available source data, indicating the business model is primarily a physical dispensing and compounding operation rather than a technology-led platform. Certifications, payer contracts, and partnership arrangements are not disclosed in source materials. The product surface is concentrated in specialty medication access and preparation for complex conditions.

Avella's commercial mechanics are not publicly disclosed. Pricing is not documented as publicly available, revenue figures are absent from source data, and no go-to-motion, channel mix, or contract economics are described. The company operates as a private entity with no disclosed ownership, investor base, or parent company relationships. Available evidence supports the conclusion that Avella is an established, operationally-focused specialty pharmacy whose competitive position is grounded in regulatory compliance, sterile compounding capability, and clinical patient support rather than in technology differentiation or aggressive commercial expansion.

Name

Avella Specialty Pharmacy

Website

https://avella.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

Avella Specialty Pharmacy is a Phoenix-based specialty and compounding pharmacy founded in 1996 that provides FDA-compliant sterile compounding and personalized medications, including hepatitis and oncology therapies, for patients requiring customized pharmaceutical formulations.

Ownership category

akta.pro rank

Product category

Specialty Pharmacy Services

NAICS

Pharmacies and Drug Retailers (45611)

SIC

Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industry

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

Keywords

• Specialty pharmacy services
• Compounding pharmacy
• Sterile medication compounding
• Oncology pharmacy medications
• Hepatitis pharmacy medications

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Core offering

Avella Specialty Pharmacy dispenses specialty pharmaceutical medications, with particular focus on hepatitis and oncology therapies, alongside personalized and compounded formulations for patients whose needs cannot be met by FDA-approved commercially available medications. The company leverages sterile compounding capabilities and FDA-compliant facilities to deliver tailored medication solutions and patient support.

Differentiator

Problem solved

Functional benefit

Products and services

• Hepatitis Medications and Support Specialty pharmacy dispensing of hepatitis medications along with associated patient support, targeted at patients with hepatitis requiring specialized therapy beyond standard commercial pharmacy offerings.
• Oncology Medications and Support Specialty pharmacy dispensing of oncology medications and patient support services for patients undergoing cancer treatment who require specialty therapies and personalized medication management.
• Sterile Compounded Medications Sterile compounding of customized medications produced in FDA-compliant facilities for patients whose needs cannot be met by FDA-approved commercial drugs.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• Fagron N.V. Global leader in pharmaceutical compounding and personalized medication, supplying pharmacies, hospitals, and prescribers. Explicitly cited alongside Avella as a key player in the U.S. compounding pharmacy market.
• TNH Specialty Pharmacy: Specialty pharmacy serving chronic and complex conditions including hepatitis and oncology, with personalized clinical support. Comparable in therapeutic mix and mid-scale specialty positioning.
• Diplomat Pharmacy (now part of Optum): Was one of the largest independent U.S. specialty pharmacies focused on oncology, immunology, and complex therapies before being acquired by Optum. Highly comparable in therapeutic mix and specialty/compounding orientation to Avella.
• BioPlus Specialty Pharmacy: Specialty pharmacy focused on complex conditions including oncology, hepatitis, and autoimmune diseases, providing clinical support and adherence programs. Closely comparable in therapeutic focus to Avella.
• Clinigen Group: Specialty pharmaceutical services and clinical trial supply company with compounding and unlicensed medicine capabilities. Explicitly cited alongside Avella as a key player in the U.S. compounding pharmacy market.

Emerging players

• SMP Pharmacy Solutions (Stadtlanders): Specialty and compounding pharmacy focused on complex patient needs, including HIV and oncology. Comparable as a regional/specialty pharmacy with compounding capability in similar therapeutic areas.

Broad incumbents

• PharMerica: Institutional pharmacy services provider serving long-term care and specialty needs, including complex therapies. Comparable as a scaled pharmacy services platform with specialty/compounding overlap.
• Walgreens Specialty Pharmacy: Specialty pharmacy offering of Walgreens Boots Alliance focused on complex, high-cost therapies with national distribution. A large, national-scale competitor in the same specialty dispensing category.
• CVS Specialty: Specialty pharmacy of CVS Health, one of the largest U.S. specialty pharmacy providers covering complex conditions including oncology, MS, and hepatitis. Represents the vertically integrated, PBM-aligned model Avella competes against.
• Optum Specialty Pharmacy: Specialty pharmacy arm of UnitedHealth Group/Optum Rx focused on complex therapies including oncology and autoimmune conditions. A vertically integrated, payer-aligned competitor that serves as a benchmark for at-scale specialty pharmacy operations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/avellarx
• Facebookfacebook.com/avellarx
• LinkedInlinkedin.com/company/avella

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avella Specialty Pharmacy